Axiom Catalyst

Join us as we discuss the latest developments in RCC coming out of ESMO22. In this episode, we recap the impact of 3 failed checkpoint-based regimen trials within the (neo)adjuvant setting and the first positive triplet data for advanced RCC.

Join us as Rohan and Andrew discuss key takeaways from an impactful ESMO22 in NSCLC. In this episode, we recap the first Phase III data for a KRASG12C inhibitor, long-term follow-up from checkpoint-based regimens, and the first ADC approval in lung.

Dr. Hope Rugo, University of California at San Francisco, joins Hafiz Sikder for an engaging discussion on the world of Breast Cancer. The discussion ranges from key ESMO data, the future of care, and healthcare disparities.

Join in this week as we review key data-set from ESMO as well as a deep dive into RCC, lung and pan-tumor discussions. Join in the discussion with your POV, comments, and questions.

Axiom Catalyst is live from Gustave Roussy! Hafiz Sikder joins Dr. Barlesi and the leading cancer treatment team in Villejuif, France for a discussion on the future of oncology.

Live from the congress floor! Join Mahim Misra and Maressa Cumbermack for part 2 of our ASCO Snacks series, a quick download on the day’s most exciting events. Axiom Catalyst will record live at the 2022 American Society of Clinical Oncology’s Annual Meeting in Chicago.

Live from the congress floor! Join Mahim Misra, Charlotte Caine, and Maressa Cumbermack for part 1 of our ASCO Snacks series, a quick download on the day’s most exciting events. Axiom Catalyst will record live at the 2022 American Society of Clinical Oncology’s Annual Meeting in Chicago.

Vicky Kuo, MS, and Rohan Gidvani, PhD, join Hafiz and Mahim this week to discuss cell and gene therapy before ASCO 2022. Tune in for insights on challenges and emerging technologies from the Axiom Table.

Dr. Hossein Borghaei, Fox Chase Cancer Center, joins Hafiz and Mahim today to discuss updates in TIGIT, Immunotherapy, and more.

On Wednesday April 27, ASCO released 2800+ abstract titles spanning all major tumor types. On today’s podcast, we will give you a glimpse into some of the impactful abstracts that will be presented at ASCO in June. Topics will range from practice changing Phase III results from ADCs to emerging modalities like CAR-engineered allogeneic γδ T cells.